POTASSIUM BICARBONATE- potassium bicarbonate tablet, effervescent

Valsts: Amerikas Savienotās Valstis

Valoda: angļu

Klimata pārmaiņas: NLM (National Library of Medicine)

Aktīvā sastāvdaļa:

Potassium Bicarbonate (UNII: HM5Z15LEBN) (Potassium Cation - UNII:295O53K152)

Pieejams no:

Upsher-Smith Laboratories, Inc.

SNN (starptautisko nepatentēto nosaukumu):

Potassium Bicarbonate

Kompozīcija:

Potassium Cation 978 mg

Ievadīšanas:

ORAL

Receptes veids:

PRESCRIPTION DRUG

Ārstēšanas norādes:

- For the treatment of patients with hypokalemia, with or without metabolic alkalosis; in digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. - For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop (e.g., digitalized patients or patients with significant cardiac arrhythmias). The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarra

Produktu pārskats:

KLOR-CON® /EF Potassium Bicarbonate Effervescent Tablets for Oral Solution, USP are supplied in cartons of 30 individually wrapped tablets (NDC 0245-0039-30) and cartons of 100 individually wrapped tablets (NDC 0245-0039-01). Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].

Autorizācija statuss:

unapproved drug other

Produkta apraksts

POTASSIUM BICARBONATE- POTASSIUM BICARBONATE TABLET, EFFERVESCENT
UPSHER-SMITH LABORATORIES, INC.
_Disclaimer: This drug has not been found by FDA to be safe and
effective, and this labeling has not been_
_approved by FDA. For further information about unapproved drugs,
click here._
----------
KLOR-CON /EF
POTASSIUM BICARBONATE EFFERVESCENT
TABLETS FOR ORAL SOLUTION, USP
RX ONLY
DESCRIPTION
Orange-flavored KLOR-CON /EF Potassium Bicarbonate Effervescent
Tablets for Oral Solution, USP
are an oral potassium supplement offered as effervescent tablets in
individual packets for dissolution in
water. Each tablet contains potassium bicarbonate 2.5 g and citric
acid 2 .1 g which in solution provides
25 mEq (978 mg) potassium as bicarbonate and citrate. Also contains:
FD&C Yellow No. 6, FD&C
Yellow No. 6 Lake, microcrystalline cellulose, mineral oil, orange
flavor, saccharin and talc. KLOR-
CON /EF tablets are sugar-free.
CLINICAL PHARMACOLOGY
The potassium ion is the principal intracellular cation of most body
tissues. Potassium ions participate
in a number of essential physiological processes, including the
maintenance of intracellular tonicity, the
transmission of nerve impulses, the contraction of cardiac, skeletal
and smooth muscle and the
maintenance of normal renal function.
The intracellular concentration of potassium is approximately 150 to
160 mEq per liter. The normal
adult plasma concentration is 3.5 to 5 mEq per liter. An active ion
transport system maintains this gradient
across the plasma membrane.
Potassium is a normal dietary constituent and under steady state
conditions the amount of potassium
absorbed from the gastrointestinal tract is equal to the amount
excreted in the urine. The usual dietary
intake of potassium is 50 to 100 mEq per day.
Potassium depletion will occur whenever the rate of potassium loss
through renal excretion and/or loss
from the gastrointestinal tract exceeds the rate of potassium intake.
Such depletion usually develops as a
consequence of therapy with diuretics, primary or seconda